Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Faron Secures U.S. Rights to Patent Related to Traumakine
Details : The agreement clarifies Faron's intellectual property position in the U.S. ahead of any launch of Traumakine for the treatment of capillary leak and systemic inflammatory response syndromes including acute respiratory distress syndrome (ARDS) in the U.S.
Product Name : Traumakine
Product Type : Protein
Upfront Cash : Undisclosed
May 14, 2021
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Interferon Beta-1A,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Action is being taken after an interim review of safety data by the study’s DSMB found an imbalance of serious adverse events among patients on high-flow oxygen/non-invasive mechanical ventilation who received interferon beta-1a vs those who did not re...
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 29, 2020
Lead Product(s) : Interferon Beta-1A,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interferon Beta-1A,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NIH Clinical Trial Testing Remdesivir Plus Interferon Beta-1a for COVID-19 Treatment Begins
Details : ACTT began on Feb. 21 to evaluate remdesivir, an investigational broad-spectrum antiviral discovered and developed by Gilead Sciences, Inc, of Foster City, California.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Interferon Beta-1A,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Company will present 54 abstracts at the meeting, taking place virtually from September 11-13, 2020, including new efficacy and real-world safety data on MAVENCLAD® (cladribine) tablets and new safety data for Rebif® (interferon beta-1a).
Product Name : Rebif
Product Type : Protein
Upfront Cash : Inapplicable
March 09, 2020
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
